GlassScriptPhysician profile
Scott Schroeder
NPI 1346220654
$9,019.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,497 · 2020: $295 · 2021: $149 · 2022: $78.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $8,098.68 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $259.38 | 2019-2021 | |
| Glaxosmithkline, LLC. | $146.84 | 2019-2021 | |
| Abbvie INC. | $112.36 | 2019-2021 | |
| Chiesi USA, INC. | $84.93 | 2020-2022 | |
| Gilead Sciences, INC. | $69.92 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $60.97 | 2019 | |
| Genzyme Corporation | $60.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $58.01 | 2019 | |
| Mallinckrodt Enterprises LLC | $28.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.09 | 2019 | |
| Acadia Pharmaceuticals INC | $14.73 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.